Highlights the unique potential of Celularity’s proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstructionSupports broad range of regenerative medicine applications beyond ophthalmology FLORHAM PARK, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced its research published in the May 29, 2025, issue of the peer-reviewed journal Regenerative ...

Core Points - Celularity Inc. has been notified by Nasdaq for not timely filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025, resulting in non-compliance with Listing Rule 5250 (c)(1) [1] - The notice from Nasdaq does not have an immediate effect on the listing or trading of the Company's shares, and the Company has 60 calendar days to submit a compliance plan [2] - The Company is actively working to complete its Form 10-Q and anticipates maintaining compliance with SEC reporting obligations [3] Company Overview - Celularity Inc. is a regenerative and cellular medicine company focused on developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, utilizing the postpartum placenta [4]

Exhibit 99.1 Celularity Announces Full Year 2024 Operating and Financial Results ● Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year. FLORHAM PARK, N.J., [DATE], May 9, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced operating and financial results for the year ended December 31, 2024. "We built momentum through ...

Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year.FLORHAM PARK, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced operating and financial results for the year ended December 31, 2024. “We built momentum through 2024 and ended the year with a strong finish, as reflected in higher net revenues from the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) 170 Park Ave Florham Park, NJ 07932 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification No.) Regist ...

Core Points - Celularity Inc. has been notified by Nasdaq regarding non-payment of fees and potential delisting unless an appeal is made [1] - The company has a past due fee balance of $70,000, which was paid in full on April 25, 2025 [1] - Nasdaq also indicated that Celularity is delinquent in filing its Form 10-K for the year ended December 31, 2024, which could lead to additional delisting actions [2] - The company is actively working to file the 2024 Form 10-K and expects to do so imminently [3] Company Overview - Celularity Inc. is a regenerative and cellular medicine company focused on developing and commercializing advanced biomaterial products and placental-derived cell therapies [4] - The company aims to leverage the unique biology of the placenta to create therapeutic solutions that meet significant global healthcare needs [4]

Core Points - The Centers for Medicare & Medicaid Services (CMS) has revised the effective date of the Medicare Local Coverage Determination (LCD) for skin substitute products to January 1, 2026, which is used to treat diabetic foot ulcers and venous leg ulcers [1][3] - This action follows a January 2025 executive order by President Trump that froze all regulatory guidance not yet in effect, leading to a previous delay of the LCD's effective date by sixty days [3] - Celularity Inc. expressed support for CMS's decision, highlighting the importance of access to skin substitute products for Medicare patients to avoid serious health complications [4] Company Overview - Celularity Inc. is a regenerative and cellular medicine company focused on developing and commercializing advanced biomaterial products and placental-derived cell therapies [5] - The company aims to leverage the unique biology of the placenta to create effective, accessible, and affordable therapeutic solutions for significant unmet global health needs [5]

Core Insights - Celularity Inc. has highlighted the therapeutic potential of its clinical-stage candidate CYNK-001 in addressing age-related diseases, as discussed in a recent publication in Frontiers in Immunology [1][2]. Group 1: Research Findings - The publication titled "Senescence, NK cells, and cancer: navigating the crossroads of aging and disease" explores the impact of aging on the immune system's ability to combat cancer, emphasizing the importance of maintaining Natural Killer (NK) cell function for healthy aging and longevity [2]. - The concept of "senoablation" is introduced, which involves the elimination of senescent cells that contribute to inflammation and malignant transformation, thereby rejuvenating the aging immune system [3]. Group 2: Clinical Development - CYNK-001, a placental-derived allogeneic NK cell therapy, has been studied in over 70 subjects with acceptable safety, indicating its potential as a treatment for conditions associated with cellular senescence, such as age-related frailty and sarcopenia [3]. - The company aims to leverage the unique biology of the placenta to develop effective and accessible therapies for significant unmet medical needs [4].

Core Insights - Celularity Inc. has received recommendation letters from the FDA's Tissue Reference Group for its products Natalin and Acelagraft™, confirming they meet the criteria for regulation under section 361 of the PHS Act [1][5] - Natalin is a tri-layer graft and Acelagraft™ is a bi-layer graft, both indicated for treating partial and full thickness acute and chronic wounds [2] - The global Biological Skin Substitutes market was valued at $347.75 million in 2024 and is projected to grow at a CAGR of 8.83% to reach $810.50 million by 2034, with the chronic wounds segment expected to grow at a 9.13% CAGR [3] Company Overview - Celularity Inc. specializes in regenerative and cellular medicine, focusing on advanced biomaterial products and placental-derived cell therapies [6] - The company aims to leverage the unique biology of the placenta to develop effective and affordable therapeutic solutions for unmet global health needs [6] Market Context - North America accounted for 42.0% of the global Biological Skin Substitutes market in 2024, indicating a significant market presence [3]

Core Insights - Celularity Inc. has entered into a Master Services Collaboration Agreement with BlueSphere Bio, Inc. to manufacture certain cell therapy products, showcasing its advanced cGMP manufacturing capabilities [1][2] - The collaboration will focus on producing BlueSphere's novel T cell receptor (TCR) therapies, including a product for treating Acute Myelogenous Leukemia (AML) [2][3] - Celularity aims to leverage its manufacturing infrastructure to attract clients and generate revenue, while BlueSphere emphasizes the importance of reliable manufacturing for its clinical programs [3][5] Company Overview - Celularity Inc. specializes in regenerative and cellular medicine, developing placental-derived cell therapies and biomaterial products [4] - The company utilizes postpartum placenta to create therapeutic solutions addressing unmet global healthcare needs [4] BlueSphere Bio Overview - BlueSphere Bio is focused on drug development, particularly in AML, with its lead product BSB-1001 targeting specific antigens in high-risk patients [5][6] - The company is advancing its clinical programs, including TCX-101 and TCX-102, with plans to dose its first patient in 1H2025 [5][6]